{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:15Z","timestamp":1790314215088,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Nigeria, declining responsiveness to artemether\u2013lumefantrine (AL), the artemisinin-based combination therapy (ACT) of choice since 2005, has been reported. Pyronaridine\u2013artesunate (PA) is a newer fixed-dose ACT recently prequalified by the WHO for the treatment of uncomplicated falciparum malaria. However, PA data from the Nigerian pediatric population is scarce. Therefore, the efficacy and safety of PA and AL using the WHO 28-day anti-malarial therapeutic efficacy study protocol in Ibadan, southwest Nigeria, were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In an open-labelled, randomized, controlled clinical trial, 172 children aged 3\u2013144\u00a0months with a history of fever and microscopically confirmed uncomplicated\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria were enrolled in southwest Nigeria. Enrollees were randomly assigned to receive PA or AL at standard dosages according to body weight for 3\u00a0days. Venous blood was obtained for hematology, blood chemistry, and liver function tests on days 0, 3, 7, and 28 as part of the safety evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>165 (95.9%) of the enrolled individuals completed the study. About half (52.3%; 90\/172) of enrollees were male. Eighty-seven (50.6%) received AL, while 85 (49.4%) received PA. Day 28, adequate clinical and parasitological response for PA was 92.7% [(76\/82) 95% CI 83.1, 95.9] and 71.1% [(59\/83) 95% CI 60.4, 79.9] for AL (0.001). Fever and parasite clearance were similar in both groups. Two of six and eight of 24 parasite recurrences were observed among PA- and AL-treated children, respectively. PCR-corrected Day-28 cure rates for PA were 97.4% (76\/78) and 88.1% (59\/67) for AL (=\u20090.04) in the per-protocol population after new infections were censored. Hematological recovery at day 28 was significantly better among PA-treated patients (34.9% 2.8) compared to those treated with AL (33.1% 3.0) (0.002). Adverse events in both treatment arms were mild and similar to the symptoms of malaria infection. Blood chemistry and liver function tests were mostly within normal limits, with an occasional marginal rise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PA and AL were well-tolerated. PA was significantly more efficacious than AL in both the PCR-uncorrected and PCR-corrected per-protocol populations during this study. The results of this study support the inclusion of PA in the anti-malarial treatment guidelines in Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Retrospective trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov: NCT05192265.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-023-04574-7","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T06:02:16Z","timestamp":1683957736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of pyronaridine\u2013artesunate versus artemether\u2013lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct05192265","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Catherine O.","family":"Falade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebola E.","family":"Orimadegun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiyinfoluwa I.","family":"Olusola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaro S.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwafunmibi E.","family":"Anjorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland I.","family":"Funwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aduragbenro D.","family":"Adedapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola L.","family":"Olusanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bose E.","family":"Orimadegun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbenga A.","family":"Mokuolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"key":"4574_CR1","unstructured":"WHO. World malaria report 2021. Geneva: World Health Organization; 2021."},{"key":"4574_CR2","unstructured":"WHO. Guidelines for malaria. WHO\/UCN\/GMP\/2021.01. Geneva: World Health Organization; 2021."},{"key":"4574_CR3","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"4574_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"4574_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","volume":"19","author":"WL Hamilton","year":"2019","unstructured":"Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect Dis. 2019;19:943\u201351.","journal-title":"Lancet Infect Dis"},{"key":"4574_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12936-016-1636-4","volume":"15","author":"N Mishra","year":"2016","unstructured":"Mishra N, Bharti RS, Mallick P, Singh OP, Srivastava B, Rana R, et al. Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern region of India. Malar J. 2016;15:583.","journal-title":"Malar J"},{"key":"4574_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether\u2013lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"4574_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4574_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, van Loon W, Habarugira F, Tacoli C, J\u00e4ger JC, Savelsberg D, et al. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis. 2021;27:294\u20136.","journal-title":"Emerg Infect Dis"},{"key":"4574_CR10","doi-asserted-by":"publisher","first-page":"2305062","DOI":"10.1155\/2018\/2305062","volume":"2018","author":"MA Oboh","year":"2018","unstructured":"Oboh MA, Ndiaye D, Antony HA, Badiane AS, Singh US, Ali NA, Bharti PK, Das A. Status of artemisinin resistance in malaria parasite Plasmodium falciparum from molecular analyses of the kelch13 gene in Southwestern Nigeria. Biomed Res Int. 2018;2018:2305062.","journal-title":"Biomed Res Int"},{"key":"4574_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/tropicalmed5020085","volume":"5","author":"UF Abubakar","year":"2020","unstructured":"Abubakar UF, Adam R, Mukhtar MM, Muhammad A, Yahuza AA, Ibrahim SS. Identification of mutations in antimalarial resistance gene kelch13 from Plasmodium falciparum isolates in Kano. Nigeria Trop Med Infect Dis. 2020;5:85.","journal-title":"Nigeria Trop Med Infect Dis"},{"key":"4574_CR12","doi-asserted-by":"crossref","unstructured":"Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009, 2009: Cd007483.","DOI":"10.1002\/14651858.CD007483.pub2"},{"key":"4574_CR13","unstructured":"Federal Ministry of Health, Nigeria. National Guidelines for Diagnosis and Treatment of Malaria. Abuja, Nigeria; 2020."},{"key":"4574_CR14","doi-asserted-by":"crossref","unstructured":"Whitty CJ, Staedke SG. Artemisinin-based combination treatment for malaria in Africa. no perfect solutions. Clin Infect Dis. 2005; 41:1087\u20138.","DOI":"10.1086\/444464"},{"key":"4574_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/inthealth\/ihv017","volume":"7","author":"E Pelfrene","year":"2015","unstructured":"Pelfrene E, Pinheiro M-H, Cavaleri M. Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency. Int Health. 2015;7:239\u201346.","journal-title":"Int Health"},{"key":"4574_CR16","unstructured":"Committee for Medicinal Products for Human Use (CHMP), Summary of opinion. Pyramax (pyronaridine tetraphosphate\/artesunate). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2012\/02\/WC500122945.pdf."},{"key":"4574_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1475-2875-11-364","volume":"11","author":"K Kayentao","year":"2012","unstructured":"Kayentao K, Doumbo OK, P\u00e9nali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine\u2013artesunate granules versus artemether\u2013lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.","journal-title":"Malar J"},{"key":"4574_CR18","doi-asserted-by":"publisher","first-page":"e14501","DOI":"10.1371\/journal.pone.0014501","volume":"6","author":"Y Poravuth","year":"2011","unstructured":"Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine\u2013artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS ONE. 2011;6:e14501.","journal-title":"PLoS ONE"},{"key":"4574_CR19","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","volume":"366","author":"R Rueangweerayut","year":"2012","unstructured":"Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al. Pyronaridine\u2013artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012;366:1298\u2013309.","journal-title":"N Engl J Med"},{"key":"4574_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","volume":"375","author":"AK Tshefu","year":"2010","unstructured":"Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine\u2013artesunate compared with artemether\u2013lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457\u201367.","journal-title":"Lancet"},{"key":"4574_CR21","unstructured":"West African Network for Clinical Trials of Antimalarial Drugs. Pyronaridine\u2013artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet. 2018; 391:1378\u201390."},{"key":"4574_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1475-2875-12-70","volume":"12","author":"S Duparc","year":"2013","unstructured":"Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin C-S, et al. Safety and efficacy of pyronaridine\u2013artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J. 2013;12:70.","journal-title":"Malar J"},{"key":"4574_CR23","unstructured":"WHO. The use of artesunate\u2013pyronaridine for the treatment of uncomplicated malaria. Geneva: World Health Organization; 2020. WHO\/HTM\/GMP\/2019.13. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/328762\/WHO-HTM-GMP-2019.13-eng.pdf."},{"key":"4574_CR24","doi-asserted-by":"publisher","first-page":"e1003669","DOI":"10.1371\/journal.pmed.1003669","volume":"18","author":"G Tona Lutete","year":"2021","unstructured":"Tona Lutete G, Mombo-Ngoma G, Assi S-B, Bigoga JD, Koukouikila-Koussounda F, Ntamabyaliro NY, et al. Pyronaridine\u2013artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study. PLoS Med. 2021;18:e1003669.","journal-title":"PLoS Med"},{"key":"4574_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40249-019-0577-x","volume":"8","author":"A Sowunmi","year":"2019","unstructured":"Sowunmi A, Ntadom G, Akano K, Ibironke FO, Ayede AI, Agomo C, et al. Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria. Infect Dis Poverty. 2019;8:69.","journal-title":"Infect Dis Poverty"},{"key":"4574_CR26","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. http:\/\/whqlibdoc.who.int\/hq\/2003\/WHO_HTM_RBM_2003.50.pdf."},{"key":"4574_CR27","doi-asserted-by":"crossref","unstructured":"WHO. Severe malaria. Trop Med Int Health. 2014;19 Suppl 1:7\u2013131.","DOI":"10.1111\/tmi.12313_2"},{"key":"4574_CR28","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2007. http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241596305_eng.pdf."},{"key":"4574_CR29","doi-asserted-by":"crossref","unstructured":"Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993; 61:315\u201320.","DOI":"10.1016\/0166-6851(93)90077-B"},{"key":"4574_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-017-2149-5","volume":"17","author":"RI Funwei","year":"2018","unstructured":"Funwei RI, Thomas BN, Falade CO, Ojurongbe O. Extensive diversity in the allelic frequency of Plasmodium falciparum merozoite surface proteins and glutamate-rich protein in rural and urban settings of southwestern Nigeria. Malar J. 2018;17:1.","journal-title":"Malar J"},{"key":"4574_CR31","doi-asserted-by":"crossref","unstructured":"Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong , Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg. 1999;93:369\u201374.","DOI":"10.1016\/S0035-9203(99)90120-7"},{"key":"4574_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.33314\/jnhrc.v17i4.1042","volume":"17","author":"B Shrestha","year":"2019","unstructured":"Shrestha B, Dunn L. The declaration of Helsinki on medical research involving human subjects: a review of seventh revision. J Nepal Health Res Council. 2019;17:548\u201352.","journal-title":"J Nepal Health Res Council"},{"key":"4574_CR33","doi-asserted-by":"crossref","unstructured":"Chow S-C, Shao J, Wang H, Lokhnygina Y. Large sample tests for proportion. In: Sample size calculations in clinical research. 3rd edn. New York: Taylor & Francis; 2018.","DOI":"10.1201\/9781315183084"},{"key":"4574_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/02724936.1992.11747561","volume":"12","author":"A Sowunmi","year":"1992","unstructured":"Sowunmi A, Walker O, Salako LA. Hyperparasitaemia: not a reliable indicator of severity or poor prognosis in falciparum malaria in children in endemic African countries. Ann Trop Paediatr. 1992;12:155\u20138.","journal-title":"Ann Trop Paediatr"},{"key":"4574_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/00034983.2000.11813577","volume":"94","author":"A Sowunmi","year":"2000","unstructured":"Sowunmi A, Adedeji AA, Sowunmi CO, Falade AG, Sijuade AO, Oduola AM. Comparative clinical characteristics and response to oral antimalarial therapy of children with and without Plasmodium falciparum hyperparasitaemia in an endemic area. Ann Trop Med Parasitol. 2000;94:549\u201358.","journal-title":"Ann Trop Med Parasitol"},{"key":"4574_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1751-553X.2011.01398.x","volume":"34","author":"N Tangpukdee","year":"2012","unstructured":"Tangpukdee N, Krudsood S, Kano S, Wilairatana P. Falciparum malaria parasitemia index for predicting severe malaria. Int J Lab Hematol. 2012;34:320\u20137.","journal-title":"Int J Lab Hematol"},{"key":"4574_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12936-018-2340-3","volume":"17","author":"JM Roth","year":"2018","unstructured":"Roth JM, Sawa P, Makio N, Omweri G, Osoti V, Okach S, et al. Pyronaridine\u2013artesunate and artemether\u2013lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. Malar J. 2018;17:199.","journal-title":"Malar J"},{"key":"4574_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1086\/591096","volume":"198","author":"M Ramharter","year":"2008","unstructured":"Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, et al. Fixed-dose pyronaridine\u2013artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198:911\u20139.","journal-title":"J Infect Dis"},{"key":"4574_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.trstmh.2004.09.013","volume":"99","author":"C Falade","year":"2005","unstructured":"Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI. Efficacy and safety of artemether\u2013lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005;99:459\u201367.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4574_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/1475-2875-7-246","volume":"7","author":"CO Falade","year":"2008","unstructured":"Falade CO, Ogunkunle OO, Dada-Adegbola HO, Falade AG, de Palacios PI, Hunt P, et al. Evaluation of the efficacy and safety of artemether\u2013lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children. Malar J. 2008;7:246.","journal-title":"Malar J"},{"key":"4574_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000360578","volume":"23","author":"CO Falade","year":"2014","unstructured":"Falade CO, Dada-Adegbola HO, Ogunkunle OO, Oguike MC, Nash O, Ademowo OG. Evaluation of the comparative efficacy and safety of artemether\u2013lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo) for the treatment of acute uncomplicated malaria in Nigerian children. Med Princ Pract. 2014;23:204\u201311.","journal-title":"Med Princ Pract"},{"key":"4574_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4269\/ajtmh.13-0248","volume":"91","author":"S Oguche","year":"2014","unstructured":"Oguche S, Okafor HU, Watila I, Meremikwu M, Agomo P, Ogala W, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children. Am J Trop Med Hyg. 2014;91:925\u201335.","journal-title":"Am J Trop Med Hyg"},{"key":"4574_CR43","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva: World Health Organization; 2018. WHO\/CDS\/GMP\/2018.18. https:\/\/apps.who.int\/iris\/handle\/10665\/274362."},{"key":"4574_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","volume":"16","author":"I Sagara","year":"2016","unstructured":"Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine\u2013artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16:189\u201398.","journal-title":"Lancet Infect Dis"},{"key":"4574_CR45","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ijpara.2010.05.004","volume":"40","author":"A Kone","year":"2010","unstructured":"Kone A, van de Vegte-Bolmer M, Siebelink-Stoter R, van Gemert G-J, Dara A, Niangaly H, et al. Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival. Int J Parasitol. 2010;40:1221\u20138.","journal-title":"Int J Parasitol"},{"key":"4574_CR46","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ijpara.2010.04.010","volume":"40","author":"AH Beavogui","year":"2010","unstructured":"Beavogui AH, Djimde AA, Gregson A, Toure AM, Dao A, Coulibaly B, et al. Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol. 2010;40:1213\u201320.","journal-title":"Int J Parasitol"},{"key":"4574_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12916-016-0641-3","volume":"14","author":"HA Karunajeewa","year":"2016","unstructured":"Karunajeewa HA, Mueller I. How important is gametocyte clearance after malaria therapy? BMC Med. 2016;14:93.","journal-title":"BMC Med"},{"issue":"14","key":"4574_CR48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","volume":"2016","author":"WWARN Gametocyte Study Group","year":"2016","unstructured":"WWARN Gametocyte Study Group. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;2016(14):79.","journal-title":"BMC Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04574-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04574-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04574-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T06:02:50Z","timestamp":1683957770000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04574-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4574"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04574-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1664143\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Ibadan\/University College Hospital Ethics Committee (EC approval No.\u2014UI\/EC\/19\/0114) and the Oyo State Ministry of Health Ethics Committee (EC approval No.\u2014AD 13\/479\/206) both approved the study protocol. Individual written informed consent was obtained from eligible participants' parents or guardians. The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki [\n                      \n                      ], as well as applicable regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declared not having any financial relationships with any organizations that might have an interest in the submitted work in the previous 3\u00a0years, no other relationships or activities that could appear to have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}